Skip to main content
Current Research in Microbial Sciences logoLink to Current Research in Microbial Sciences
. 2026 Feb 1;10:100566. doi: 10.1016/j.crmicr.2026.100566

Fimbriae potentiate Aggregatibacter actinomycetemcomitans for periodontal disease

Yanyan Fu 1, Qiqi Pan 1, Jan Maarten van Dijl 1,
PMCID: PMC12905792  PMID: 41695579

Highlights

  • Aggregatibacter actinomycetemcomitans is a causative agent of periodontitis.

  • Fimbriae are key modulators of A. actinomycetemcomitans virulence.

  • Fimbriae drive aggregation, colonization, immune evasion and pathogenicity.

  • Fimbriae limit bacterial vesicle and extracellular cytoplasmic protein release.

  • Fimbriae are key therapeutic targets to control periodontal disease.

Keywords: Aggregatibacter actinomycetemcomitans, Fimbriae, Virulence

Abstract

Aggregatibacter actinomycetemcomitans is a major contributor to aggressive periodontitis and has been increasingly implicated in systemic conditions, such as rheumatoid arthritis and Alzheimer’s disease. Among its diverse virulence mechanisms, fimbriae have emerged as central factors driving colonization, immune evasion, and pathogenicity. This review highlights recent findings showing that fimbriae not only facilitate adhesion and biofilm formation, but also contribute to maintaining bacterial cell envelope integrity. The transition from rough (fimbriated) to smooth (non-fimbriated) colony phenotypes upon in vitro culturing is associated with significant changes in virulence, including increased release of outer membrane vesicles (OMVs) and extracellular cytoplasmic proteins (ECPs). These changes suggest a trade-off between surface structure expression and secretion-based virulence. Importantly, fimbriae-rich strains are clinically relevant and more virulent in host models. The combined evidence implies that fimbriae and key virulence factors, such as leukotoxin A, act cooperatively in pathogenesis, as fimbriae-mediated adhesion and persistence will enhance local toxin delivery, killing of immune cells and immune evasion. Together, these insights point to fimbriae as key targets for novel therapeutic and vaccination strategies aimed at controlling periodontal and related systemic diseases.

Graphical abstract

Image, graphical abstract

Periodontitis – the most prevalent neglected disease

The most prevalent disease on planet earth, periodontitis, is an inflammatory disease that irreversibly destroys the soft tissues and bone surrounding our teeth (Könönen et al., 2019). Localized aggressive forms of periodontitis lead to tooth destruction, especially the permanent first molars and incisors of teenagers and young adults (Fine et al., 2019). Periodontitis has been associated with a dysbiosis of the oral microbial community that colonizes the hard surfaces of teeth and the mucosal tissues of the oral cavity (Fu et al., 2022). In healthy individuals, the oral microbiota co-evolves with the host, leading to a harmonious coexistence of the different microorganisms and the periodontal tissues (Di Stefano et al., 2022). However, once this balance is broken due to lifestyle factors, including inadequate oral hygiene, unhealthy diets and smoking, or due to the use of antibiotics, the oral microbiota will change (Santonocito et al., 2022). The resulting oral dysbiosis creates a favorable environment for oral pathogens, such as Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, which will trigger further changes of the microbial communities and lead to periodontal inflammation and destruction (Di Stefano et al., 2022; Xu et al., 2025). Such pathogens may even impact on the behavior of other pathogens that are unrelated to periodontitis, as was recently reported for the major human pathogen Staphylococcus aureus, which was shown to aggregate due to the binding of outer membrane vesicles (OMVs) excreted by P. gingivalis (du Teil Espina et al., 2022). As bacterial aggregation is a first step towards biofilm formation, the latter observation underscores the view that an increasing abundance of oral pathogens like P. gingivalis can have serious repercussions for infection of the oral cavity and beyond (du Teil Espina et al., 2022). Of note, A. actinomycetemcomitans is a facultative anaerobe, in contrast to many other major periodontal pathogens, such as P. gingivalis, that are obligate anaerobes. This metabolic flexibility gives A. actinomycetemcomitans the possibility to colonize oxygenated niches in the periodontal pocket, allowing early biofilm development. Consequently, A. actinomycetemcomitans will have a competitive advantage, as obligate anaerobic periopathogens preferentially establish themselves later within oxygen-depleted environments of the periodontal pocket.

Importantly, there are significant differences in the composition of the oral microbiota in individuals with mild or severe periodontitis (Plachokova et al., 2021). This reflects the fact that some bacteria have a higher propensity to cause inflammation than other bacteria. Accordingly, the outgrowth of some notorious oral pathogens, like P. gingivalis and A. actinomycetemcomitans, is strongly associated with systemic inflammation even though their abundance may remain relatively low (Cortelli et al., 2020; Fine et al., 2020).

A. actinomycetemcomitans – an evolving pathogen

A. actinomycetemcomitans has attracted attention, because it is associated with aggressive forms of periodontitis in young adults (Nørskov-Lauritsen et al., 2019). In general, the preferred ecological niche of A. actinomycetemcomitans is the oral cavity (van Winkelhoff et al., 1993). However, it may translocate across the epithelial barrier, causing dangerous infections of the blood, heart valves, joints, soft tissues, bone and brain (Nedergaard et al., 2019; Sharma et al., 2017; Rahamat-Langendoen et al., 2011). Moreover, A. actinomycetemcomitans has also been implicated in severely debilitating systemic diseases, such as the autoimmune disorder rheumatoid arthritis (RA) and Alzheimer’s diseases (Looh et al., 2022; Díaz-Zúñiga et al., 2019).

A. actinomycetemcomitans is a genetically highly adaptable bacterium (Kittichotirat et al., 2016; Chen et al., 2020). This was first evidenced by serotyping, which revealed the existence of at least seven different serotypes (named a to g) that show variations in the O-antigen of their lipopolysaccharides (LPS) (Tsuzukibashi et al., 2014). The serotypes a, b and c are most commonly encountered. However, their prevalence varies with geographical locations and ethnicity. For instance, in the UK and Turkey, the serotype a is most common (Akrivopoulou et al., 2017; Doğan et al., 2016). In Morocco (Haubek et al., 2008), Spain (Mínguez et al., 2014), Germany (Kim et al., 2009) and India (Suprith et al., 2018) the serotype b is predominant. In many Asian countries, such as China (Mombelli et al., 1999), Japan (Wang et al., 2005; Yoshida et al., 2003), Thailand (Pahumunto et al., 2015) and Korea (Kim et al., 2009), as well as Brazil (Roman-Torres et al., 2010) and the USA (Chen et al., 2010), serotype c isolates are most frequent. Serotype variations are associated with differential clinical manifestations and the pathogenicity of A. actinomycetemcomitans. Isolates with the serotype b are often cultured from patients with severe periodontitis (Haubek et al., 2008; Cortelli et al., 2012), and their high virulence has been confirmed in vitro infection experiments (Monasterio et al., 2018; Díaz-Zúñiga et al., 2017).

In recent years, the phylogenetic divergence and genomic plasticity of A. actinomycetemcomitans isolates have become more clearly evident by (whole-genome) sequencing. This allows a distinction of five clades that overlap with the known serotypes: clade a/d includes isolates with serotypes a and d, clade b includes serotype b isolates, clade c includes serotype c isolates, clade e/f includes serotype e and f isolates, and clade e’ represents an outgroup of serotype e isolates (Kittichotirat et al., 2016; Kittichotirat et al., 2011). Furthermore, amongst isolates with serotypes a, b and c, three lineages were distinguished. Lineage I includes isolates related with serotypes b and c, lineage II includes the ‘common’ serotype a isolates, and lineage III includes ‘aberrant’ serotype a isolates (Nedergaard et al., 2019; Fu et al., 2023). Interestingly, isolates of lineage II are competent for genetic transformation (Nedergaard et al., 2019), suggesting that this mechanism for horizontal gene transfer (HGT) has contributed to the exchange and subsequent evolution of genomic islands in A. actinomycetemcomitans. In addition, prophages have been described for this bacterium, which implicate transduction by phages in HGT as well (Stevens et al., 2013). Genetic exchange by HGT probably led to the evolution of at least two serotype-specific genomic islands with distinct genes located at different loci in serotype a and serotype b-f isolates (Kittichotirat et al., 2022). The idea that phages have shaped the evolution of A. actinomycetemcomitans can also be inferred from the identification of genes for ‘clustered regularly interspaced short palindromic repeats’ (CRISPRs) and the expression of CRISPR-associated proteins in the common serotype a isolates (Fu et al., 2023). These CRISPRs and related proteins could be involved in phage immunity, but they may also contribute to virulence as was shown for Campylobacter jejuni (Saha et al., 2020). To visualize the evolutionary relationships among strains, a phylogenetic tree was constructed using marker genes of A. actinomycetemcomitans retrieved from the UniRef90 database, comprising a total of 186 strains. These included 29 serotype a strains, 85 serotype b strains, 29 serotype c strains, 8 serotype d strains, 11 serotype e strains, 16 serotype f strains, 1 serotype g strain, and 7 strains with unknown serotypes. Aggregatibacter aphrophilus ATCC 33,389 was used as the outgroup for tree rooting. As shown in Fig. 1, the majority of serotype b isolates formed a distinct cluster, with only three strains diverging from the main group. Most serotype c strains clustered closely and were positioned near the serotype b group, suggesting a close evolutionary relationship. Serotype a strains largely clustered with serotype d strains, indicating potential phylogenetic relatedness. A subset of serotype e strains grouped together with the majority of serotype f strains, forming a separate cluster.

Fig. 1.

Fig. 1 dummy alt text

Circular phylogenetic tree of A. actinomycetemcomitans. The tree is based on marker genes of A. actinomycetemcomitans retrieved from the UniRef90 database. It was generated using PhyloPhlAn (v3.1.1) and visualized with iTOL (http://itol.embl.de/). Isolates characterized by integrated proteomics, virulence and immune evasion analyses are marked by color-coded bullets in the outer circles (Fu et al., 2023; Y. Fu et al., 2022).

Leukotoxin A of A. actinomycetemcomitans

An important genomic island of A. actinomycetemcomitans carries the ltxCABD operon that encodes the major leukotoxin A (LtxA) and its associated secretion system. Also for this island, serotype- and clade-specific differences have been reported (Kittichotirat et al., 2022). In addition, a genetic variation within this island in serotype b isolates, referred to as the JP2 genotype, is related to severe periodontitis in young individuals (Haubek et al., 2008; Khzam et al., 2022). In particular, a deletion of 530 base pairs (bp) in the promotor region of the ltxCABD operon of JP2 isolates leads to overexpression of LtxA and enhanced leukotoxicity (Tsai et al., 2018). Genomic plasticity is also associated with elevated LtxA expression and progressive periodontitis observed in a Swedish cohort study, as evidenced for a subgroup of non-JP2 serotype b isolates of A. actinomycetemcomitans that carry the cagE gene (Johansson et al., 2017; Johansson et al., 2019). Moreover, two additional mutations in the ltxCABD promotor leading to higher LtxA production and leukotoxicity were recently recognized, involving deletions of 640 or 230 bp, respectively (Claesson et al., 2020; Claesson et al., 2015). Additional ltxCABD promotor mutations with varying effects on leukotoxicity were identified (Claesson et al., 2020; He et al., 1998), underpinning the view that such mutations can shape the virulence of A. actinomycetemcomitans. Here it is noteworthy that this type of mutations seem to occur quite frequently, as one study detected 33 ltxCABD promoter mutations amongst 693 A. actinomycetemcomitans isolates, with 30 of them belonging to the JP2 genotype (Claesson et al., 2020).

While LtxA is generally regarded as a major virulence factor of A. actinomycetemcomitans, the research documented in recent studies shows that it is certainly not the only important virulence factor. In particular, combined proteomics studies and infection experiments with strains belonging to serotypes a, b or c (marked in Fig. 1) show that certain isolates that produce relatively low levels of LtxA are apparently more virulent than other isolates that produce relatively high levels of LtxA (Fu et al., 2023). Nonetheless, previous studies have reported a compelling association between LtxA production and the clinical presentation of A. actinomycetemcomitans. Isolates from patients with aggressive periodontitis tended to produce high levels of LtxA, whereas isolates from healthy individuals tended to produce much lower LtxA levels (Haubek et al., 2008). Importantly, individuals carrying A. actinomycetemcomitans with the highly leukotoxic JP2 genotype showed a substantially increased odds ratio for clinical attachment loss and aggressive periodontitis compared to carriers of non-JP2 strains (Haubek et al., 2008; Mínguez et al., 2014). The markedly elevated odds ratio underscores the notion that specific A. actinomycetemcomitans genotypes/phenotypes, including high-level LtxA expression, are strongly associated with severe periodontal tissue destruction. In addition, high LtxA expression levels were also associated with the onset and progression of periodontitis (Khzam et al., 2022; Fine et al., 2019).

In initial studies, LtxA was reported to specifically target immune cells from humans or Old World primates, including neutrophils, macrophages and lymphocytes (Vega et al., 2019; Ozuna et al., 2021; Kelk et al., 2022). Neutrophils are the immune cells that form a first line of defense against invasive pathogens and, accordingly, they form the majority of leukocytes recruited into infected periodontal pockets (Jiang et al., 2021). Upon exposure to LtxA, neutrophils will release various granule components, including the neutrophil elastase (NE). This protease is present in elevated amounts in the saliva of periodontitis patients and eventually causes detachment and death of human gingival epithelial cells and human gingival fibroblasts (Hiyoshi et al., 2019). Moreover, LtxA provokes the release of neutrophil extracellular traps (NETs) (Hirschfeld et al., 2016), which induces periodontitis and further tissue destruction (Wang et al., 2021). Intriguingly, LtxA was shown to trigger hypercitrullination through the release of human peptidyl-arginine deiminases by the LtxA-affected neutrophils. These enzymes catalyze the conversion of positively charged arginine residues into neutral citrulline residues, a feature that has been implicated in the onset of RA which is characterized by high levels of auto-antibodies against citrullinated proteins (Konig et al., 2016). In macrophages, LtxA was shown to activate the ‘nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3′ (NLRP3) inflammasome, which can induce bone resorption and pro-inflammatory cell death (Kelk et al., 2022). However, the detrimental effects of LtxA are not limited to immune cells, since it also shows toxicity towards endothelial cells and erythrocytes at high concentrations (Looh et al., 2022; Krueger and Brown, 2020). These observations clearly associate LtxA with periodontitis, periodontal tissue destruction, and eventually systemic diseases, such as RA.

Two distinct phenotypes of A. actinomycetemcomitans

As the genus name Aggregatibacter indicates, clinical A. actinomycetemcomitans isolates tend to aggregate, forming small granules in broth and biofilms on the walls of culture vessels (Fig. 2B,C). On solid media, the isolates form small rough colonies with a characteristic star-shaped and transparent appearance (Fig. 2A). However, after a few passages in the laboratory, the rough colony phenotype is lost and the bacteria form larger smooth colonies with an opaque appearance. The resulting strains with the smooth colony phenotype form homogeneous cultures in broth (Fig. 2B). Although essentially all clinical isolates of A. actinomycetemcomitans have the rough colony phenotype, a 2001 review referred to nine invasive clinical isolates with the smooth phenotype (Kachlany et al., 2001). However, this is certainly not the case for all invasive A. actinomycetemcomitans isolates, since two serotype c isolates that were recently collected from tissue of a sternum wound and thoracic pus at the University Medical Center Groningen, the Netherlands, presented the rough colony phenotype. Altogether, to the best of our knowledge, A. actinomycetemcomitans bacteria with the smooth colony phenotype have not been isolated from the oral cavity of patients with periodontitis. However, we cannot exclude the possibility that A. actinomycetemcomitans bacteria without fimbriae or with low-level fimbriation do occasionally emerge in the oral cavity.

Fig. 2.

Fig. 2 dummy alt text

Features of clinical A. actinomycetemcomitans isolates. Clinical isolates of A. actinomycetemcomitans cultured on brain heart infusion (BHI) agar supplemented with 5 % l-cysteine, 5 mg/L hemin and 1 mg/L menadione and grown at 37 °C and 5 % CO2 for three days form small colonies that display a star shape upon scraping. The image in panel A was taken with a light microscope at 100x magnification. Upon 40 h culturing in BHI broth with the same supplementation, A. actinomycetemcomitans with the rough (R) colony phenotype presents granules in the broth (B) and biofilms on the walls of the tube (C). In contrast, A. actinomycetemcomitans with the smooth (S) colony phenotype forms homogeneous cultures in BHI broth (B).

The rough colony phenotype is dependent on the expression of fimbriae with a diameter of 6 to 7 nm and variable length (Fu et al., 2022; Fine et al., 1999; Wang et al., 2005). As was shown by transmission electron microscopy (TEM) in Fig. 3, A. actinomycetemcomitans bacteria with the rough colony phenotype present bundles of long and thick fimbriae on their cell surface, while their smooth derivatives display short, thin or even no fimbriae. The fimbrial biogenesis in A. actinomycetemcomitans is controlled by the flp operon, which includes 14 genes (flp-1-flp-2-tadV-rcpCAB-tadZABCDEFG) (Danforth et al., 2019). Genome sequencing showed that smooth strains contain mutations in the flp promotor region, the repair of which leads to a restoration of the rough colony phenotype (Fu et al., 2022; Wang et al., 2005). Nine genes in the flp operon (i.e.flp-1, rcpA, rcpB, tadB, tadD, tadE and tadF) are indispensable for expression of fimbriae, while strains lacking the other five genes (i.e.flp-2, tadZ, tadA, tadC and tadG) display reduced fimbriation, or fimbriae with a different appearance (Perez et al., 2006; Wang and Chen, 2005). For one smooth strain, it was observed that the flp-1 to tadC genes were lost during rough-to-smooth conversion (Fu et al., 2022). To date, only one study has reported reversion of the smooth to the rough colony phenotype upon culturing on a low-humidity solid medium (Pei et al., 2013). The respective reverted bacteria expressed fimbriae, but did not present star-shaped colonies. Unfortunately, the reversions were not identified by sequencing but, in case of point mutations in the flp promoter region, it is not surprising that reverted bacteria with the rough phenotype may appear. Notably, the rough to smooth conversion can be observed within six passages on BHI broth, which suggests that genetic instability is a general trait of A. actinomycetemcomitans, as can also be inferred from the rapid appearance of mutations in the ltxCABD promoter region.

Fig. 3.

Fig. 3 dummy alt text

Morphology of A. actinomycetemcomitans bacteria with the rough or smooth colony phenotypes.A. actinomycetemcomitans bacteria with the rough or smooth colony phenotypes were grown in BHI broth and subsequently imaged by transmission electron microscopy after negative staining with uranyl acetate. Size bars indicate the magnification. The arrow marks fimbriae of bacteria with the rough colony phenotype.

Interestingly, A. actinomycetemcomitans bacteria with the smooth or rough colony phenotypes can differ not only in fimbrial expression and adhesion, but also in the localization and delivery of LtxA (Fu et al., 2022). A. actinomycetemcomitans isolates with the rough colony phenotype that expressed LtxA at high levels displayed LtxA retention to the cells, whereas derivative strains with the smooth colony phenotype released nearly all LtxA into their extracellular milieu (Fu et al., 2022). This suggests that highly fimbriated strains are more prone to retain LtxA in association with the bacterial outer membrane, which may have important consequences for virulence.

Fimbriae are crucial for A. actinomycetemcomitans

Fimbrial appendages on the bacterial cell surface facilitate interactions between pathogens and the cells and tissues of their host. Such interactions are important for host colonization and the onset of infection (Reed and Williams, 1978; Sharma et al., 2021). In A. actinomycetemcomitans the fimbriae also facilitate auto-aggregation and the formation of biofilms, leading to persistent colonization of periodontal tissues and bacterial evasion of periodontal treatment with antimicrobial agents (Pourhajibagher et al., 2018). Furthermore, flp-1 and tadA mutants, which lack fimbriae, failed to colonize the oral cavity of rats, did not elicit immune responses in rats, and did not cause bone loss in a murine infection model (Schreiner et al., 2003). This aligns well with the afore-mentioned notion that LtxA can be retained to the cells by fimbriae (Fu et al., 2022), thereby indirectly increasing the local toxin exposure at sites where the bacteria adhere to epithelial surfaces and immune cells. By enhancing colonization density and persistence within periodontal niches, fimbriae will thus potentiate leukocyte killing and immune evasion by LtxA. For another oral pathogen, P. gingivalis, the fimbrial adhesins are also known to be important for binding to other microbes, colonization of tissues, nutrient acquisition and invasion of immune cells and host tissues (Meghil et al., 2022). These observations together with recent findings showing reduced virulence of smooth A. actinomycetemcomitans strains compared to the respective parental isolates with the rough colony phenotype (Fu et al., 2022) imply that the disruption of fimbrial functions could be a very effective approach to prevent or treat periodontitis, and to prevent periodontitis-associated diseases that involve the bacterial translocation to non-oral body sites (Heidler et al., 2021).

Outer membrane vesicles (OMVs)

OMVs are produced naturally by Gram-negative bacteria. Such vesicles are spheroid particles with a diameter of around 10–300 nm. The OMVs are pinched off from the cell envelope and, accordingly, they contain phospholipids, LPS and proteins. However, they also contain nucleic acids (Avila-Calderón et al., 2021).

OMVs have been reported to serve many different functions in nutrient acquisition, cell-cell communication, bacterial aggregation, biofilm formation, antibacterial activity, virulence, the evasion of host immune responses and antimicrobial resistance (Monteiro et al., 2025; Peregrino et al., 2024). In accordance with these functions, multiple OMV-associated virulence factors involved in immunoreactivity and proinflammatory activity, cytotoxicity, adhesion and invasion, immune evasion, drug targeting and the scavenging of iron and nutrients were identified by proteome analyses (Kieselbach et al., 2015; Fu et al., 2025). In particular, the OMVs of A. actinomycetemcomitans were proposed to act as vehicles for delivery of the virulence factors LtxA and cytolethal distending toxin (CDT) into human host cells (Rompikuntal et al., 2012; Nice et al., 2018). CDT is a genotoxic virulence factor that induces DNA damage-mediated cell-cycle arrest and apoptosis in epithelial and immune cells (Boesze-Battaglia et al., 2016). The DNase-like activity of the CdtB subunit disrupts host cell turnover and immune competence, which may provoke chronic inflammation and periodontal tissue breakdown (Boesze-Battaglia et al., 2016). CDT is therefore regarded as a factor that contributes to impaired host defense and disease persistence in the periodontal environment. Furthermore, OMVs of A. actinomycetemcomitans were shown to induce the ‘nucleotide-binding oligomerization domain-containing protein 1′ (NOD1)- and NOD2-dependent NF-κB activation, which has been implicated in alveolar bone resorption (Thay et al., 2014). OMVs from A. actinomycetemcomitans were also shown to provide serum protection, allowing the bacteria to translocate from the oral cavity to other body sites (Lindholm et al., 2020).

OMVs from A. actinomycetemcomitans can be internalized by non-phagocytic host cells, such as HeLa cells and human gingival fibroblasts, via multiple pathways including clathrin-mediated endocytosis and fusion with plasma membranes in a cholesterol-dependent process (Rompikuntal et al., 2012; Thay et al., 2014). In this context, it is noteworthy that the internalization of OMVs from A. actinomycetemcomitans into host cells was LtxA- or CDT-independent (Rompikuntal et al., 2012; Demuth et al., 2003). Furthermore, the LPS from A. actinomycetemcomitans has been implicated in the binding of interleukin-8, which may allow OMVs to influence the migration of neutrophils (Ahlstrand et al., 2019). Other OMV cargo from A. actinomycetemcomitans that may influence the behavior of host cells are small RNA molecules of microRNA size (msRNAs) that can modulate the host immune response (Ha et al., 2020; Choi et al., 2017; Han et al., 2019). Accordingly, such extracellular RNAs (exRNAs) may be regarded as biomarkers for systemic diseases (Lee, 2020). Interestingly, OMVs from A. actinomycetemcomitans were, for instance, shown to cross the blood-brain barrier (BBB) after intracardiac injection and exRNAs contained in these OMVs were implicated in the activation of TNF-α in the mouse brain cortex (Han et al., 2019). Furthermore, OMV-associated exRNAs were delivered into meningeal macrophages and cortex microglial cells in a time-sequential manner upon tail-vein injection in a murine infection model, and such exRNAs induced the release of proinflammatory cytokine IL-6 in a murine microglial cell line (Ha et al., 2020). Altogether, these findings underpin the view that A. actinomycetemcomitans is not only involved in periodontitis, but that this bacterium may also act as a causative agent in systemic diseases through the strategic transfer of many different virulence factors, including proteins, LPS and RNA, over long distances with the help of OMVs.

Fimbriae block the excretion of extracellular cytoplasmic proteins (ECPs)

Consistent with the important role of OMVs in the virulence of A. actinomycetemcomitans, the proteins that the bacteria release into their extracellular milieu, collectively referred to as the exoproteome, should be regarded as an important reservoir of virulence factors. This notion inspired extensive exoproteome analyses by mass spectrometry (MS). Interestingly, the MS analyses did not only uncover typical secretory proteins, or periplasmic and (outer) membrane proteins that can be associated with OMVs, but also many cytoplasmic proteins. Such extracellular cytoplasmic proteins (ECPs) may serve dual ‘moonlighting’ functions inside and outside the bacterial cell, for instance in the adhesion to host cells and tissues or detoxification of the environment (Ebner and Götz, 2019). However, ECPs may also be regarded as a sign of bacterial lysis. Interestingly, A. actinomycetemcomitans bacteria with the smooth colony phenotype excreted substantially more extracellular cytoplasmic proteins than bacteria with the rough colony phenotype. The simplest explanation for this observation is that bacteria with the smooth phenotype are more prone to lysis due to their reduced fimbriation. This would suggest that fimbriae serve an important role in maintaining the bacterial integrity, in addition to their adhesive functions. Conversely, the excretion of ECPs that could also promote adhesion to cells and tissues of the host might reflect a bacterial strategy to compensate, at least to some extent, for the absence of fimbriae. In any case, the enhanced release of ECPs by smooth colony variants of A. actinomycetemcomitans could not be associated with the other known mechanisms implicated in this process, such as (pro)phage activity or the secretion of cell envelope-destabilizing autolysins or toxins (Ebner and Götz, 2019; Ebner et al., 2017; Zhao et al., 2019; Schlag et al., 2010). The view that fimbriae counteract the excretion of ECPs is supported by the observation that A. actinomycetemcomitans isolates with the serotype a excreted significantly more ECPs than isolates with the serotypes b or c, whereas fewer fimbriae-associated proteins were identified for isolates with the serotype a (Fu et al., 2023). Interestingly, OMVs of A. actinomycetemcomitans carry also substantial amounts of ECPs, whereas bacteria with the smooth colony phenotype excrete substantially more OMVs than bacteria with the rough phenotype. Thus, there seems to be an intimate relationship between the release of OMVs and ECPs, which suggests that cell envelope destabilization is a main cause of ECP excretion in A. actinomycetemcomitans.

The high-level excretion of ECPs by non-fimbriated strains is not an exclusive trait of A. actinomycetemcomitans, since it is observed in at least one other oral pathogen, namely P. gingivalis (Stobernack et al., 2016). P. gingivalis expresses long and short fimbriae, which are also known as the major and minor fimbriae, respectively (Meghil et al., 2022). The major fimbrial subunit protein type-1 (FimA) was not identified in the reference strains W83 and MDS45, which present higher numbers of identified ECPs than the fimbriated strain ATCC 33,277 expressing FimA (Stobernack et al., 2016).

Despite the higher amounts of ECPs excreted by A. actinomycetemcomitans with the smooth colony phenotype, which could be regarded as a sign of bacterial lysis, these smooth strains grow much better in broth than the parental strains with the rough colony phenotype (Fig. 2). This implies that the smooth strains are fitter for culturing under laboratory conditions. Likewise, it has been reported that an Escherichia colistrain lacking fimbriae grew better compared with its parental strain, and that gene expression was generally upregulated in the non-fimbriated mutant (Qiao et al., 2021). This is in accordance with the fact that the synthesis and assembly of fimbriae require energy that cannot be used for other processes. Furthermore, fimbriae may alter the physiochemical properties of the bacterial cell surface. These ideas are fully in line with the different phenotypes of A. actinomycetemcomitans with the rough and smooth colony phenotypes (Fig. 1). Likewise, assembly of the so-called CupD fimbriae on the surface of Pseudomonas aeruginosa was shown to result in a small colony morphotype, increased biofilm formation and decreased motility (Mikkelsen et al., 2009).

Lastly, while more ECPs were produced by A. actinomycetemcomitans strains with the smooth phenotype, isolates with the rough colony phenotype produced more extracellular virulence factors (Fu et al., 2023; Fu et al., 2022). This is in accordance with the infectious behavior of the rough isolates in humans, whereas the isolation of smooth strains from humans has not been verifiably documented. Based on these observations, it can be concluded that fimbriae are the key virulence factors of A. actinomycetemcomitans, a view that is fully supported by the correlation of the exoproteome data and in vitro virulence assays with human neutrophils and gingival epithelial cells (Fu et al., 2023; Fu et al., 2022). In this context it is important to note that, while ECP excretion is a prominent feature of A. actinomycetemcomitans bacteria with the smooth colony phenotype, this does not mean that bacteria with the rough colony phenotype do not release ECPs - they merely release lower amounts of ECPs. Therefore, even though the smooth colony phenotype of A. actinomycetemcomitans is essentially observed under in vitro laboratory conditions, experimental comparisons between smooth and rough colony variants provide important mechanistic insights into virulence regulation and the potential contribution of ECPs to virulence. Clearly, the rough and smooth colony phenotypes reflect distinct regulatory and structural states that influence the bacterial surface architecture, extracellular protein secretion and outer membrane properties. Differences in ECP release between smooth and rough strains therefore illuminate how alterations in the bacterial envelope modulate the localization and delivery of virulence factors, such as LtxA. Thus, it seems that fimbriae influence the bacterial virulence not only by mediating adhesion, but also by modulating the spatial distribution and functional impact of ECPs and OMVs. Potentially, fimbrial structures may facilitate the local retention of secreted virulence factors at the bacterial surface, thereby creating a protective microenvironment that limits immune clearance, while also enabling concentrated delivery of OMV-associated toxins, such as LtxA and CDT, to host cells either in close proximity or at sites distant from the bacterium.

Concluding remarks and future perspectives – fimbriae as druggable targets

Altogether, recent studies provide a deeper understanding of the contributions of extracellular proteins to the morphological features, growth behavior and virulence of different A. actinomycetemcomitans isolates belonging to the globally predominant serotypes a, b and c (Fu et al., 2023; Fu et al., 2022). The results also show how OMVs of A. actinomycetemcomitans interact with human neutrophils, provoking them to prematurely discharge their antimicrobial armory represented by NETs and antimicrobial proteins (Fu et al., 2025). It thus seems that OMVs serve an important immune evasive function for A. actinomycetemcomitans in the oral cavity. Importantly, the correlation of identified virulence factors and the virulence of A. actinomycetemcomitans in different in vitro infection models highlights the key virulence factors of this pathogen, especially the fimbriae-associated proteins. Since fimbriae are primarily known to serve attachment functions, it seems plausible that they are needed to bring the bacteria and cells of the host in close proximity, such that virulence factors like LtxA and CDT can execute their cytotoxic effects. Possibly, the fimbrial proteins included in OMVs also facilitate association of these bacterial satellites with host cells, but this remains to be shown in future studies. In any case, the observations presented in this review suggest that the bacterial fimbriae are prime targets for preventive and therapeutic interventions against the pathogen A. actinomycetemcomitans. In particular, disruption of the interactions between the pili and the host cells using small molecule drugs or immunization approaches could provide added value by complementing the present-day treatments based on periodontal care and surgical interventions.

Vaccination is one of the most effective strategies to control and reduce the mortality and morbidity caused by infectious diseases (Cid and Bolívar, 2021). The conventional approaches include live-attenuated, inactivated, subunit and toxoid vaccines that generally target proteins and capsule polysaccharides on the bacterial cell surface (Wadhwa et al., 2020). On the other hand, novel more sophisticated vaccines involve the delivery of DNA or RNA to the host, such that the host will produce relevant antigens of the pathogen (Wadhwa et al., 2020). As can be concluded from the major success in fighting the recent Covid-19 pandemic, messenger RNA (mRNA)-based vaccines are highly attractive for addressing infectious diseases due to their efficacy, safety and ease of delivery (Deng et al., 2022). Hence, it is an attractive idea to develop such vaccines also for the treatment of bacterial infections, including recurring periodontal disease. Fimbrial subunits and particular toxins of A. actinomycetemcomitans appear to be attractive targets for such vaccines. Fimbriae have been previously explored as vaccine antigens in different bacterial pathogens, where anti-fimbrial immunity can block adhesion and colonization (Gorringe and Vaughan, 2014). The most prominent example in human medicine is the acellular pertussis vaccine, in which the fimbrial antigens Fim2 and Fim3 contribute to protection by limiting respiratory tract colonization by Bordetella pertussis (Alexander et al., 2012; Hallander et al., 2014). In parallel, fimbriae-based vaccines have long been established as the gold standard in veterinary medicine for the prevention of enteric E. coliinfections in livestock, providing compelling real-world evidence that neutralization of these surface adhesion structures effectively prevents severe diarrheal disease (Broeck et al., 1999).

Despite the successes, the broader application of fimbriae-based vaccines has been constrained by antigenic and phase variation, whereby bacteria alter fimbrial expression or structure to evade host immunity (Tajuelo et al., 2024). This limitation will necessitate the targeting of conserved adhesive elements rather than entire fimbriae. This view is supported by studies on vaccines that specifically target fimbrial tip-associated adhesins, such as the FimH-containing FimCH complex. In this case, clinical follow-up studies reported up to 75 % reduction in recurrent urinary tract infections caused by antibiotic resistant Enterobacteriaceae (Perer et al., 2024). Furthermore, another study indicated that immunization of mice with the FimA and MrkA subunits from fimbriae of Klebsiella pneumoniae significantly reduced the severity of infections in a pneumonia model (Assoni et al., 2025).

Following up on this line of reasoning, a combined vaccine targeting fimbriae and LtxA of A. actinomycetemcomitans could simultaneously inhibit adhesion of the bacteria to the human tissues and neutralize a major toxin. Such a multicomponent strategy may provide broader protection than single-antigen vaccines. Inhibiting the virulence of A. actinomycetemcomitans bacteria with a competitive harmless non-virulent A. actinomycetemcomitans strain would also be worth investigating but, in this case, it would be necessary that the bacteria can still adhere to the periodontal tissues, which requires the expression of fimbriae. It is presently uncertain whether such a non-virulent strain that is completely safe for application in humans can be developed and we anticipate regulatory hurdles for administrating non-virulent A. actinomycetemcomitans to patients. In that sense, a more promising strategy might be the identification of probiotic bacteria that can outcompete A. actinomycetemcomitans in the oral cavity.

Vaccination against A. actinomycetemcomitans and P. gingivalis could also be beneficial for the prevention of systemic diseases associated with periodontitis. This view is supported by a cohort study, which showed that patients with early and established RA presented increased levels of anti-LtxA IgM compared with matched non-RA controls and periodontally healthy individuals. The anti-LtxA IgM levels were associated with early-stage RA, suggesting a link between A. actinomycetemcomitans and systemic diseases (Gomez-Bañuelos et al., 2020). However, before vaccination approaches against A. actinomycetemcomitans can be developed, it will be important to determine carefully whether they are safe and which individuals will benefit the most from them. Clearly, since periodontal disease is one of the most wide-spread diseases at the global scale, with people in developing countries being most severely affected, the development of alternative treatments based on relatively cheap antimicrobial drugs or disinfectants should also be considered next to vaccine development.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Yanyan Fu reports financial support was provided by the China Scholarship Council. Qiqi Pan reports financial support was provided by the China Scholarship Council. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors acknowledge Sjouke Piersma and Anouk H. G. Wolters for helping take the EM pictures in Fig. 3. Y. Fu and Q. Pan were supported by the China Scholarship Council (grant 201808110197 to Y.F. and grant 202206790018 to Q. P.) and a fellowship of the Graduate School of Medical Sciences of the University of Groningen.

References

  1. Ahlstrand T., et al. Aggregatibacter actinomycetemcomitans LPS binds human interleukin-8. J. Oral. Microbiol. 2019;11(1) doi: 10.1080/20002297.2018.1549931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Akrivopoulou C., et al. Aggregatibacter actinomycetemcomitans serotype prevalence and antibiotic resistance in a UK population with periodontitis. J. Glob. Antimicrob. Resist. 2017;10:54–58. doi: 10.1016/j.jgar.2017.03.011. [DOI] [PubMed] [Google Scholar]
  3. Alexander F., et al. Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease. Clin. Vaccine Immunol. 2012;19(11):1776–1783. doi: 10.1128/CVI.00355-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Assoni L., et al. Protection Against Pneumonia Induced by Vaccination with Fimbriae Subunits from Klebsiella pneumoniae. Vaccines. (Basel) 2025;13(3) doi: 10.3390/vaccines13030303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Avila-Calderón E.D., et al. Outer Membrane Vesicles of Gram-Negative Bacteria: an Outlook on Biogenesis. Front. Microbiol. 2021;12 doi: 10.3389/fmicb.2021.557902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boesze-Battaglia K., et al. A Journey of Cytolethal Distending Toxins through Cell Membranes. Front. Cell Infect. Microbiol. 2016;6:81. doi: 10.3389/fcimb.2016.00081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Broeck W.V.d., Cox E., Goddeeris B.M. Receptor-Dependent Immune Responses in Pigs after Oral Immunization with F4 Fimbriae. Infect. Immun. 1999;67(2):520–526. doi: 10.1128/iai.67.2.520-526.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chen C., Feng P., Slots J. Herpesvirus-bacteria synergistic interaction in periodontitis. Periodontol. 2000. 2020;82(1):42–64. doi: 10.1111/prd.12311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen C., Wang T., Chen W. Occurrence of Aggregatibacter actinomycetemcomitans serotypes in subgingival plaque from United States subjects. Mol. Oral Microbiol. 2010;25(3):207–214. doi: 10.1111/j.2041-1014.2010.00567.x. [DOI] [PubMed] [Google Scholar]
  10. Choi J.W., et al. Secretable Small RNAs via Outer Membrane Vesicles in Periodontal Pathogens. J. Dent. Res. 2017;96(4):458–466. doi: 10.1177/0022034516685071. [DOI] [PubMed] [Google Scholar]
  11. Cid R., Bolívar J. Platforms for Production of Protein-Based Vaccines: from Classical to Next-Generation Strategies. Biomolecules. 2021;11(8) doi: 10.3390/biom11081072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Claesson R., et al. Detection of a 640-bp deletion in the Aggregatibacter actinomycetemcomitans leukotoxin promoter region in isolates from an adolescent of Ethiopian origin. J. Oral Microbiol. 2015;7 doi: 10.3402/jom.v7.26974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Claesson R., et al. Characterization of Aggregatibacter actinomycetemcomitans Serotype b Strains with Five Different, Including Two Novel, Leukotoxin Promoter Structures. Vaccines. (Basel) 2020;8(3) doi: 10.3390/vaccines8030398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cortelli J.R., et al. Aggregatibacter actinomycetemcomitans serotypes infections and periodontal conditions: a two-way assessment. Eur. J. Clin. Microbiol. Infect. Dis. 2012;31(7):1311–1318. doi: 10.1007/s10096-011-1444-2. [DOI] [PubMed] [Google Scholar]
  15. Cortelli J.R., et al. Aggregatibacter actinomycetemcomitans serotypes and JP2 outcomes related to clinical status over 6 years under periodontal maintenance therapy. Arch. Oral Biol. 2020;116 doi: 10.1016/j.archoralbio.2020.104747. [DOI] [PubMed] [Google Scholar]
  16. Danforth D.R., et al. A Nonfimbrial Adhesin of Aggregatibacter actinomycetemcomitans Mediates Biofilm Biogenesis. Infect. Immun. 2019;87(1) doi: 10.1128/IAI.00704-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Demuth D.R., et al. Interaction of Actinobacillus actinomycetemcomitans outer membrane vesicles with HL60 cells does not require leukotoxin. Cell Microbiol. 2003;5(2):111–121. doi: 10.1046/j.1462-5822.2003.00259.x. [DOI] [PubMed] [Google Scholar]
  18. Deng Z., et al. mRNA Vaccines: the Dawn of a New Era of Cancer Immunotherapy. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.887125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Díaz-Zúñiga J., et al. Differential human Th22-lymphocyte response triggered by Aggregatibacter actinomycetemcomitans serotypes. Arch. Oral Biol. 2017;78:26–33. doi: 10.1016/j.archoralbio.2017.02.008. [DOI] [PubMed] [Google Scholar]
  20. Díaz-Zúñiga J., et al. Serotype b of Aggregatibacter actinomycetemcomitans triggers pro-inflammatory responses and amyloid beta secretion in hippocampal cells: a novel link between periodontitis and Alzheimer´s disease? J. Oral Microbiol. 2019;11(1) doi: 10.1080/20002297.2019.1586423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Di Stefano M., et al. Impact of Oral Microbiome in Periodontal Health and Periodontitis: a Critical Review on Prevention and Treatment. Int. J. Mol. Sci. 2022;23(9) doi: 10.3390/ijms23095142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Doğan B., et al. Occurrence and serotype distribution of Aggregatibacter actinomycetemcomitans in subjects without periodontitis in Turkey. Arch. Oral Biol. 2016;61:125–129. doi: 10.1016/j.archoralbio.2015.10.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. du Teil Espina M., et al. Outer membrane vesicles of the oral pathogen Porphyromonas gingivalis promote aggregation and phagocytosis of Staphylococcus aureus. Front. Oral Health. 2022;3 doi: 10.3389/froh.2022.948524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ebner P., et al. Non-classical Protein Excretion Is Boosted by PSMα-Induced Cell Leakage. Cell Rep. 2017;20(6):1278–1286. doi: 10.1016/j.celrep.2017.07.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ebner P., Götz F. Bacterial Excretion of Cytoplasmic Proteins (ECP): occurrence, Mechanism, and Function. Trends. Microbiol. 2019;27(2):176–187. doi: 10.1016/j.tim.2018.10.006. [DOI] [PubMed] [Google Scholar]
  26. Fine D.H., et al. Phenotypic variation in Actinobacillus actinomycetemcomitans during laboratory growth: implications for virulence. Microbiology (Reading) 1999;145:1335–1347. doi: 10.1099/13500872-145-6-1335. (Pt 6) [DOI] [PubMed] [Google Scholar]
  27. Fine D.H., et al. Unique etiologic, demographic, and pathologic characteristics of localized aggressive periodontitis support classification as a distinct subcategory of periodontitis. J. Am. Dent. Assoc. 2019;150(11):922–931. doi: 10.1016/j.adaj.2019.07.024. [DOI] [PubMed] [Google Scholar]
  28. Fine D.H., Patil A.G., Velusamy S.K. Aggregatibacter actinomycetemcomitans (Aa) Under the Radar: myths and Misunderstandings of Aa and Its Role in Aggressive Periodontitis. Front. Immunol. 2019;10:728. doi: 10.3389/fimmu.2019.00728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Fine D.H., Schreiner H., Velusamy S.K. Aggregatibacter, A low abundance pathobiont that influences biogeography, microbial dysbiosis, and host defense capabilities in periodontitis: the history of A Bug, and localization of disease. Pathogens. 2020;9(3) doi: 10.3390/pathogens9030179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Fu Y., et al. Connections between exoproteome heterogeneity and virulence in the oral pathogen aggregatibacter actinomycetemcomitans. mSystems. 2022;7(3) doi: 10.1128/msystems.00254-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Fu Y., et al. In: Encyclopedia of Infection and Immunity. Rezaei N., editor. Elsevier: Oxford; 2022. Oral and Dental Infections: bacteria; pp. 346–362. Editor. [Google Scholar]
  32. Fu Y., et al. Differential virulence of aggregatibacter actinomycetemcomitans serotypes explained by Exoproteome heterogeneity. Microbiol. Spectr. 2023;11(1) doi: 10.1128/spectrum.03298-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Fu Y., et al. Characterization of outer membrane vesicles of Aggregatibacter actinomycetemcomitans serotypes a, b and c and their interactions with human neutrophils. Int. J. Med. Microbiol. 2025;319 doi: 10.1016/j.ijmm.2025.151655. [DOI] [PubMed] [Google Scholar]
  34. Gomez-Bañuelos E., et al. Exposure to Aggregatibacter actinomycetemcomitans before Symptom Onset and the Risk of Evolving to Rheumatoid Arthritis. J. Clin. Med. 2020;9(6) doi: 10.3390/jcm9061906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Gorringe A.R., Vaughan T.E. Bordetella pertussis fimbriae (Fim): relevance for vaccines. Expert. Rev. Vaccines. 2014;13(10):1205–1214. doi: 10.1586/14760584.2014.930667. [DOI] [PubMed] [Google Scholar]
  36. Ha J.Y., et al. Delivery of Periodontopathogenic Extracellular Vesicles to Brain Monocytes and Microglial IL-6 Promotion by RNA Cargo. Front. Mol. Biosci. 2020;7 doi: 10.3389/fmolb.2020.596366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Hallander H., et al. Antibody Responses to Bordetella pertussis Fim2 or Fim3 following Immunization with a Whole-Cell, Two-Component, or Five-Component Acellular Pertussis Vaccine and following Pertussis Disease in Children in Sweden in 1997 and 2007. Clinical and Vaccine Immunology. 2014;21(2):165–173. doi: 10.1128/CVI.00641-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Han E.C., et al. Extracellular RNAs in periodontopathogenic outer membrane vesicles promote TNF-α production in human macrophages and cross the blood-brain barrier in mice. FASEB J. 2019;33(12):13412–13422. doi: 10.1096/fj.201901575R. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Haubek D., et al. Risk of aggressive periodontitis in adolescent carriers of the JP2 clone of Aggregatibacter (Actinobacillus) actinomycetemcomitans in Morocco: a prospective longitudinal cohort study. Lancet. 2008;371(9608):237–242. doi: 10.1016/S0140-6736(08)60135-X. [DOI] [PubMed] [Google Scholar]
  40. He T., et al. Genotypic characterization of Actinobacillus actinomycetemcomitans isolated from periodontitis patients by arbitrarily primed polymerase chain reaction. J. Periodontol. 1998;69(1):69–75. doi: 10.1902/jop.1998.69.1.69. [DOI] [PubMed] [Google Scholar]
  41. Heidler T.V., et al. Porphyromonas gingivalis fimbrial protein Mfa5 contains a von Willebrand factor domain and an intramolecular isopeptide. Commun. Biol. 2021;4(1):106. doi: 10.1038/s42003-020-01621-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Hirschfeld J., et al. Effects of Aggregatibacter actinomycetemcomitans leukotoxin on neutrophil migration and extracellular trap formation. J. Oral Microbiol. 2016;8 doi: 10.3402/jom.v8.33070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Hiyoshi T., et al. Aggregatibacter actinomycetemcomitans induces detachment and death of human gingival epithelial cells and fibroblasts via elastase release following leukotoxin-dependent neutrophil lysis. Microbiol. Immunol. 2019;63(3–4):100–110. doi: 10.1111/1348-0421.12672. [DOI] [PubMed] [Google Scholar]
  44. Jiang Q., et al. Interactions between neutrophils and periodontal pathogens in late-onset periodontitis. Front. Cell Infect. Microbiol. 2021;11 doi: 10.3389/fcimb.2021.627328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Johansson A., et al. The cagE gene sequence as a diagnostic marker to identify JP2 and non-JP2 highly leukotoxic Aggregatibacter actinomycetemcomitans serotype b strains. J. Periodontal. Res. 2017;52(5):903–912. doi: 10.1111/jre.12462. [DOI] [PubMed] [Google Scholar]
  46. Johansson A., et al. Genetic Profiling of Aggregatibacter actinomycetemcomitans Serotype B Isolated from Periodontitis Patients Living in Sweden. Pathogens. 2019;8(3) doi: 10.3390/pathogens8030153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Kachlany S.C., et al. Genes for tight adherence of Actinobacillus actinomycetemcomitans: from plaque to plague to pond scum. Trends. Microbiol. 2001;9(9):429–437. doi: 10.1016/s0966-842x(01)02161-8. [DOI] [PubMed] [Google Scholar]
  48. Kelk P., et al. Aggregatibacter actinomycetemcomitans Leukotoxin Activates the NLRP3 Inflammasome and Cell-to-Cell Communication. Pathogens. 2022;11(2) doi: 10.3390/pathogens11020159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Khzam N., et al. Prevalence of the JP2 genotype of Aggregatibacter actinomycetemcomitans in the world population: a systematic review. Clin. Oral Investig. 2022;26(3):2317–2334. doi: 10.1007/s00784-021-04343-3. [DOI] [PubMed] [Google Scholar]
  50. Kieselbach T., et al. Proteomics of Aggregatibacter actinomycetemcomitans Outer Membrane Vesicles. PLoS. One. 2015;10(9) doi: 10.1371/journal.pone.0138591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Kim T.S., et al. Serotypes of Aggregatibacter actinomycetemcomitans in patients with different ethnic backgrounds. J. Periodontol. 2009;80(12):2020–2027. doi: 10.1902/jop.2009.090241. [DOI] [PubMed] [Google Scholar]
  52. Kittichotirat W., et al. Identification of the pangenome and its components in 14 distinct Aggregatibacter actinomycetemcomitans strains by comparative genomic analysis. PLoS. One. 2011;6(7) doi: 10.1371/journal.pone.0022420. p. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Kittichotirat W., Bumgarner R.E., Chen C. Evolutionary Divergence of Aggregatibacter actinomycetemcomitans. J. Dent. Res. 2016;95(1):94–101. doi: 10.1177/0022034515608163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Kittichotirat W., Bumgarner R.E., Chen C. Genomic Islands shape the genetic background of both JP2 and Non-JP2 Aggregatibacter actinomycetemcomitans. Pathogens. 2022;11(9) doi: 10.3390/pathogens11091037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Konig M.F., et al. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci. Transl. Med. 2016;8(369):369ra176. doi: 10.1126/scitranslmed.aaj1921. p. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Könönen E., Gursoy M., Gursoy U.K. Periodontitis: a Multifaceted Disease of Tooth-Supporting Tissues. J. Clin. Med. 2019;8(8) doi: 10.3390/jcm8081135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Krueger E., Brown A.C. Aggregatibacter actinomycetemcomitans leukotoxin: from mechanism to targeted anti-toxin therapeutics. Mol. Oral Microbiol. 2020;35(3):85–105. doi: 10.1111/omi.12284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Lee H.J. Microbial extracellular RNAs and their roles in human diseases. Exp. Biol. Med. (Maywood) 2020;245(10):845–850. doi: 10.1177/1535370220923585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Lindholm M., et al. Outer membrane vesicle-mediated serum protection in Aggregatibacter actinomycetemcomitans. J. Oral Microbiol. 2020;12(1) doi: 10.1080/20002297.2020.1747857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Looh S.C., et al. Aggregatibacter actinomycetemcomitans as the Aetiological Cause of Rheumatoid Arthritis: what Are the Unsolved Puzzles? Toxins. (Basel) 2022;14(1) doi: 10.3390/toxins14010050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Meghil M.M., Ghaly M., Cutler C.W. A Tale of Two Fimbriae: how Invasion of Dendritic Cells by Porphyromonas gingivalis Disrupts DC Maturation and Depolarizes the T-Cell-Mediated Immune Response. Pathogens. 2022;11(3) doi: 10.3390/pathogens11030328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Mikkelsen H., et al. Expression of Pseudomonas aeruginosa CupD fimbrial genes is antagonistically controlled by RcsB and the EAL-containing PvrR response regulators. PLoS. One. 2009;4(6):e6018. doi: 10.1371/journal.pone.0006018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Mínguez M., et al. Characterization and serotype distribution of Aggregatibacter actinomycetemcomitans isolated from a population of periodontitis patients in Spain. Arch. Oral Biol. 2014;59(12):1359–1367. doi: 10.1016/j.archoralbio.2014.07.021. [DOI] [PubMed] [Google Scholar]
  64. Mombelli A., et al. Actinobacillus actinomycetemcomitans in Chinese adults. Serotype distribution and analysis of the leukotoxin gene promoter locus. J. Clin. Periodontol. 1999;26(8):505–510. doi: 10.1034/j.1600-051x.1999.260803.x. [DOI] [PubMed] [Google Scholar]
  65. Monasterio G., et al. Alveolar bone resorption and Th1/Th17-associated immune response triggered during Aggregatibacter actinomycetemcomitans-induced experimental periodontitis are serotype-dependent. J. Periodontol. 2018;89(10):1249–1261. doi: 10.1002/JPER.17-0563. [DOI] [PubMed] [Google Scholar]
  66. Monteiro R., et al. Outer membrane vesicles of carbapenem-resistant clinical Acinetobacter baumannii isolates protect both the vesicle-producing bacteria and non-resistant bacteria against carbapenems. Microbiol. Res. 2025;297 doi: 10.1016/j.micres.2025.128175. [DOI] [PubMed] [Google Scholar]
  67. Nedergaard S., et al. Whole genome sequencing of aggregatibacter actinomycetemcomitans cultured from blood stream infections reveals three major phylogenetic groups including a novel lineage expressing serotype a membrane O polysaccharide. Pathogens. 2019;8(4) doi: 10.3390/pathogens8040256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Nice J.B., et al. Aggregatibacter actinomycetemcomitans Leukotoxin Is Delivered to Host Cells in an LFA-1-Indepdendent Manner When Associated with Outer Membrane Vesicles. Toxins. (Basel) 2018;10(10) doi: 10.3390/toxins10100414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Nørskov-Lauritsen N., et al. Aggregatibacter actinomycetemcomitans: clinical significance of a pathobiont subjected to ample changes in classification and nomenclature. Pathogens. 2019;8(4) doi: 10.3390/pathogens8040243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Ozuna H., Uriarte S.M., Demuth D.R. The hunger games: aggregatibacter actinomycetemcomitans exploits human neutrophils as an epinephrine source for survival. Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.707096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Pahumunto N., et al. Aggregatibacter actinomycetemcomitans serotypes and DGGE subtypes in Thai adults with chronic periodontitis. Arch. Oral Biol. 2015;60(12):1789–1796. doi: 10.1016/j.archoralbio.2015.09.003. [DOI] [PubMed] [Google Scholar]
  72. Pei Z., et al. Phenotypic changes in nonfimbriated smooth strains of Aggregatibacter actinomycetemcomitans grown in low-humidity solid medium. Ultrastruct. Pathol. 2013;37(2):121–126. doi: 10.3109/01913123.2012.745637. [DOI] [PubMed] [Google Scholar]
  73. Peregrino E.S., et al. The Role of Bacterial Extracellular Vesicles in the Immune Response to Pathogens, and Therapeutic Opportunities. Int. J. Mol. Sci. 2024;25(11) doi: 10.3390/ijms25116210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Perer E., et al. Case report: long-term follow-up of patients who received a FimCH vaccine for prevention of recurrent urinary tract infections caused by antibiotic resistant Enterobacteriaceae: a case report series. Front. Immunol. 2024;15 doi: 10.3389/fimmu.2024.1359738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Perez B.A., et al. Genetic analysis of the requirement for flp-2, tadV, and rcpB in Actinobacillus actinomycetemcomitans biofilm formation. J. Bacteriol. 2006;188(17):6361–6375. doi: 10.1128/JB.00496-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Plachokova A.S., et al. Oral microbiome in relation to periodontitis severity and systemic inflammation. Int. J. Mol. Sci. 2021;22(11) doi: 10.3390/ijms22115876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Pourhajibagher M., et al. Inhibitory effects of antimicrobial photodynamic therapy with curcumin on biofilm-associated gene expression profile of Aggregatibacter actinomycetemcomitans. J. Dent. (Tehran) 2018;15(3):169–177. [PMC free article] [PubMed] [Google Scholar]
  78. Qiao J., et al. Construction of an Escherichia coli strain lacking fimbriae by deleting 64 genes and its application for efficient production of Poly(3-Hydroxybutyrate) and l-threonine. Appl. Environ. Microbiol. 2021;87(12) doi: 10.1128/AEM.00381-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Rahamat-Langendoen J.C., et al. Brain abscess associated with Aggregatibacter actinomycetemcomitans: case report and review of literature. J. Clin. Periodontol. 2011;38(8):702–706. doi: 10.1111/j.1600-051X.2011.01737.x. [DOI] [PubMed] [Google Scholar]
  80. Reed W.P., Williams R.C., Jr. Bacterial adherence: first step in pathogenesis of certain infections. J. Chronic. Dis. 1978;31(2):67–72. doi: 10.1016/0021-9681(78)90091-7. [DOI] [PubMed] [Google Scholar]
  81. Roman-Torres C.V., et al. Prevalence and distribution of serotype-specific genotypes of Aggregatibacter actinomycetemcomitans in chronic periodontitis Brazilian subjects. Arch. Oral Biol. 2010;55(3):242–248. doi: 10.1016/j.archoralbio.2010.01.008. [DOI] [PubMed] [Google Scholar]
  82. Rompikuntal P.K., et al. Perinuclear localization of internalized outer membrane vesicles carrying active cytolethal distending toxin from Aggregatibacter actinomycetemcomitans. Infect. Immun. 2012;80(1):31–42. doi: 10.1128/IAI.06069-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Saha C., et al. Guide-free Cas9 from pathogenic Campylobacter jejuni bacteria causes severe damage to DNA. Sci. Adv. 2020;6(25):eaaz4849. doi: 10.1126/sciadv.aaz4849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Santonocito S., et al. A cross-talk between diet and the oral microbiome: balance of nutrition on inflammation and immune system's response during periodontitis. Nutrients. 2022;14(12) doi: 10.3390/nu14122426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Schlag M., et al. Role of staphylococcal wall teichoic acid in targeting the major autolysin Atl. Mol. Microbiol. 2010;75(4):864–873. doi: 10.1111/j.1365-2958.2009.07007.x. [DOI] [PubMed] [Google Scholar]
  86. Schreiner H.C., et al. Tight-adherence genes of Actinobacillus actinomycetemcomitans are required for virulence in a rat model. Proc. Natl. Acad. Sci. u S. a. 2003;100(12):7295–7300. doi: 10.1073/pnas.1237223100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Sharma K., et al. Aggregatibacter actinomycetemcomitans osteomyelitis in a 12 year old boy: case report emphasizing the importance of tissue culture, and review of literature. Ann. Clin. Microbiol. Antimicrob. 2017;16(1):12. doi: 10.1186/s12941-017-0186-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Sharma V., von Ossowski I., Krishnan V. Exploiting pilus-mediated bacteria-host interactions for health benefits. Mol. Aspects. Med. 2021;81 doi: 10.1016/j.mam.2021.100998. [DOI] [PubMed] [Google Scholar]
  89. Stevens R.H., et al. Prophage induction in lysogenic Aggregatibacter actinomycetemcomitans cells co-cultured with human gingival fibroblasts, and its effect on leukotoxin release. Microb. Pathog. 2013;54:54–59. doi: 10.1016/j.micpath.2012.09.005. [DOI] [PubMed] [Google Scholar]
  90. Stobernack T., et al. Extracellular Proteome and Citrullinome of the Oral Pathogen Porphyromonas gingivalis. J. Proteome Res. 2016;15(12):4532–4543. doi: 10.1021/acs.jproteome.6b00634. [DOI] [PubMed] [Google Scholar]
  91. Suprith S.S., et al. Serotypes of Aggregatibacter actinomycetemcomitans in relation to periodontal status and assessment of leukotoxin in periodontal disease: a clinico-microbiological study. J. Indian Soc. Periodontol. 2018;22(3):201–208. doi: 10.4103/jisp.jisp_36_18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Tajuelo A., et al. Deep Intraclonal Analysis for the Development of Vaccines against Drug-Resistant Klebsiella pneumoniae Lineages. Int. J. Mol. Sci. 2024;25(18):9837. doi: 10.3390/ijms25189837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Thay B., et al. Aggregatibacter actinomycetemcomitans outer membrane vesicles are internalized in human host cells and trigger NOD1- and NOD2-dependent NF-κB activation. Infect. Immun. 2014;82(10):4034–4046. doi: 10.1128/IAI.01980-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Tsai C.C., et al. Aggregatibacter (Actinobacillus) actimycetemcomitans leukotoxin and human periodontitis - A historic review with emphasis on JP2. Kaohsiung. J. Med. Sci. 2018;34(4):186–193. doi: 10.1016/j.kjms.2018.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Tsuzukibashi O., et al. A gene cluster for the synthesis of serotype g-specific polysaccharide antigen in Aggregatibacter actinomycetemcomitans. Arch. Microbiol. 2014;196(4):261–265. doi: 10.1007/s00203-014-0965-3. [DOI] [PubMed] [Google Scholar]
  96. van Winkelhoff A.J., et al. Long-standing bacteremia caused by oral Actinobacillus actinomycetemcomitans in a patient with a pacemaker. Clin. Infect. Dis. 1993;16(2):216–218. doi: 10.1093/clind/16.2.216. [DOI] [PubMed] [Google Scholar]
  97. Vega B.A., et al. Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA) Requires Death Receptor Fas, in Addition to LFA-1, To Trigger Cell Death in T Lymphocytes. Infect. Immun. 2019;87(8) doi: 10.1128/IAI.00309-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Wadhwa A., et al. Opportunities and Challenges in the Delivery of mRNA-based Vaccines. Pharmaceutics. 2020;12(2) doi: 10.3390/pharmaceutics12020102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Wang D., et al. Elevated serum IgG titer and avidity to Actinobacillus actinomycetemcomitans serotype c in Japanese periodontitis patients. Oral Microbiol. Immunol. 2005;20(3):172–179. doi: 10.1111/j.1399-302X.2005.00208.x. [DOI] [PubMed] [Google Scholar]
  100. Wang J., et al. The Role of Neutrophil Extracellular Traps in Periodontitis. Front. Cell Infect. Microbiol. 2021;11 doi: 10.3389/fcimb.2021.639144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Wang Y., Chen C. Mutation analysis of the flp operon in Actinobacillus actinomycetemcomitans. Gene. 2005;351:61–71. doi: 10.1016/j.gene.2005.02.010. [DOI] [PubMed] [Google Scholar]
  102. Wang Y., Liu A., Chen C. Genetic basis for conversion of rough-to-smooth colony morphology in Actinobacillus actinomycetemcomitans. Infect. Immun. 2005;73(6):3749–3753. doi: 10.1128/IAI.73.6.3749-3753.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Xu Q., et al. The oral-gut microbiota axis: a link in cardiometabolic diseases. NPJ. Biofilms. Microbiomes. 2025;11(1):11. doi: 10.1038/s41522-025-00646-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Yoshida Y., et al. Distribution of Actinobacillus actinomycetemcomitans serotypes and Porphyromonas gingivalis in Japanese adults. Oral Microbiol. Immunol. 2003;18(3):135–139. doi: 10.1034/j.1399-302x.2003.00034.x. [DOI] [PubMed] [Google Scholar]
  105. Zhao X., et al. Exoproteome Heterogeneity among Closely Related Staphylococcus aureus t437 Isolates and Possible Implications for Virulence. J. Proteome Res. 2019;18(7):2859–2874. doi: 10.1021/acs.jproteome.9b00179. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Current Research in Microbial Sciences are provided here courtesy of Elsevier

RESOURCES